Last week, GenomeWeb's readers were most interested in Illumina plans to launch a new chip for its NovaSeq instrument and upgrades to its iSeq sequencer in Q1.
CellMax is developing and applying its CTC platform for early detection of colorectal cancer and more long term for breast and prostate cancer.
The partnership with Finnish medical data sciences services vendor MedEngine will help BC Platforms offer end-to-end services for pharma and health-tech companies.
The VISTA T cell-inhibiting protein found on macrophage immune cells may contribute to poor pancreatic ductal adenocarcinoma outcomes, new research finds.
The issue, discovered in late October, affected TMB reporting for up to 800 FoundationOne CDx tests during a short period of time and was quickly resolved.
Novogene's Chinese clinical lab will offer LifeMap's recently updated TGex next-generation sequencing data analysis and interpretation platform.
The company plans to use the funding to further develop its Xdrop technology, which allows users to partition millions of single molecules in droplets.
The protease-activated Cas9 enzymes could reduce off-target effects and could be used to sense pathogens and trigger an immune response.
An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.
An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.
In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.
Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.